Therapeutic Targeting of SPINK1-Positive Prostate Cancer
- 2 March 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 3 (72) , 72ra17
Abstract
SPINK1 is a therapeutic target in a subset of patients with SPINK1 + /ETS − prostate cancer.Keywords
This publication has 36 references indexed in Scilit:
- ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical PracticeEuropean Urology, 2009
- ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cellsProceedings of the National Academy of Sciences, 2009
- Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesisNature Genetics, 2009
- Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateNature Genetics, 2009
- Androgen-Regulated and Highly Tumorigenic Human Prostate Cancer Cell Line Established from a Transplantable Primary CWR22 TumorClinical Cancer Research, 2008
- The Role of SPINK1 in ETS Rearrangement-Negative Prostate CancersCancer Cell, 2008
- A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate CancerCancer Research, 2008
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- Expression of tumor‐associated trypsinogens (TAT‐1 and TAT‐2) in prostate cancerThe Prostate, 2005
- Epidermal growth factor: Internal duplication and probable relationship to pancreatic secretory trypsin inhibitorBiochemical and Biophysical Research Communications, 1974